GlobeNewswire by notified

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Share

Company announcement – No. 52 / 2022

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark and Boston, MA, U.S. November 17, 2022 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Implementation of share buy-back programme1.2.2023 13:06:47 CET | Press release

Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders Date 1 February 2023 Implementation of share buy-back programme The bank’s board of directors decided today to implement a share buy-back programme totalling DKK 385 million with a view to cancelling the shares at a future general meeting. The share buyback programme is based on the general authority which the bank’s annual general meeting held the 2 March 2022 gave the bank’s board of directors to permit the bank to acquire own shares. The share buy-back programme runs from 2 February 2023 up to and including 27 July 2023 provided that the forthcoming annual general meeting, to be held on 1 March 2023, gives the board a new authority to permit the bank to acquire its own shares. During this period the bank will buy its own shares for up to DKK 385 million under the programme, subject to a maximum of 1,000,000 shares. The share buy-back programme will be implemented in compliance with Regulation (EU) No 596/2014

Iværksættelse af aktietilbagekøbsprogram1.2.2023 13:06:47 CET | pressemeddelelse

Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter Dato 1. februar 2023 Iværksættelse af aktietilbagekøbsprogram Bankens bestyrelse har i dag besluttet at iværksætte et aktietilbagekøbsprogram på i alt 385 mio. kroner med det formål at annullere disse på en senere generalforsamling. Aktietilbagekøbsprogrammet afvikles med baggrund i den generelle bemyndigelse, som bankens bestyrelse fik fra den ordinære generalforsamling afholdt den 2. marts 2022, til at lade banken erhverve egne aktier. Aktietilbagekøbsprogrammet løber i perioden fra og med den 2. februar 2023 og til og med den 27. juli 2023 under forudsætning af den kommende ordinære generalforsamlings (til afholdelse den 1. marts 2023) fornyede bemyndigelse til bestyrelsen til at lade banken erhverve egne aktier. I perioden vil banken tilbagekøbe egne aktier for op til maksimalt 385 mio. kroner, dog vil der maksimalt kunne erhverves 1.000.000 stk. aktier under aktietilbagekøbsprogrammet. Aktietilbagekøbspro

Overflytning af afdeling Advice Capital Globale fra Investeringsforeningen Investin til Investeringsforeningen Advice Capital1.2.2023 12:51:15 CET | pressemeddelelse

På ekstraordinær generalforsamling den 30. september 2022 blev det besluttet, at afdeling Advice Capital Globale i Investeringsforeningen Investin (afgivende forening) med virkning fra den 3. marts 2023 skulle overflyttes til Investeringsforeningen Advice Capital (modtagende forening). Finanstilsynet har ved brev af den 21. oktober 2022 givet tilladelse til overflytningen. Inden afdelingen overflyttes, skal årsrapport for 2022 for Investeringsforeningen Investin, hvor afdeling Advice Capital Globale indgår, endeligt godkendes af generalforsamlingen. Da ordinær generalforsamling er fastlagt til den 21. april 2023, må overflytningsdagen ændres til et senere tidspunkt. Som følge af ovenstående har bestyrelserne i henholdsvis Investeringsforeningen Investin og Investeringsforeningen Advice Capital vedtaget et tillæg til den tidligere godkendte overflytningsplan og -redegørelse om ændring af tidsplanen for overflytningen. Tidsplanen for overflytningen ændres således: AktivitetÆndres fraÆndr

Terms for Nykredit's and Totalkredit's auctions - Nykredit Realkredit A/S1.2.2023 12:20:00 CET | Press release

To Nasdaq Copenhagen Terms for Nykredit's and Totalkredit's auctions The total bond offering in connection with the interest rate adjustment of adjustable-rate mortgages (ARMs) and the refinancing of floating-rate loans at Nykredit’s and Totalkredit’s refinancing auctions amounts to approx. DKK 42bn. The auctions will be conducted in the period from 6th to 10th February 2023. In the auction period, Nykredit Realkredit A/S will publish the amounts offered in the individual ISINs daily at nykredit.com/ir. Terms for the auctions including a list of the bonds offered, amounts offered and an auction schedule appear from Appendices 1 and 2. Questions regarding the bond sale as well as technical matters may be addressed to Nykredit Realkredit A/S, Group Treasury, Christian Mauritzen, tel +45 44 55 10 14. Other questions may be addressed to Corporate Communications, tel +45 44 55 14 50. Appendix 1: Auction terms Bonds offered, amounts offered and auction schedule Appendix 2 contains auction sc

Terms for Nykredit's and Totalkredit's auctions - Totalkredit A/S1.2.2023 12:20:00 CET | Press release

To Nasdaq Copenhagen Terms for Nykredit's and Totalkredit's auctions The total bond offering in connection with the interest rate adjustment of adjustable-rate mortgages (ARMs) and the refinancing of floating-rate loans at Nykredit’s and Totalkredit’s refinancing auctions amounts to approx. DKK 42bn. The auctions will be conducted in the period from 6th to 10th February 2023. In the auction period, Nykredit Realkredit A/S will publish the amounts offered in the individual ISINs daily at nykredit.com/ir. Terms for the auctions including a list of the bonds offered, amounts offered and an auction schedule appear from Appendices 1 and 2. Questions regarding the bond sale as well as technical matters may be addressed to Nykredit Realkredit A/S, Group Treasury, Christian Mauritzen, tel +45 44 55 10 14. Other questions may be addressed to Corporate Communications, tel +45 44 55 14 50. Appendix 1: Auction terms Bonds offered, amounts offered and auction schedule Appendix 2 contains auction sc